FDA approves Illumina's companion diagnostic for Amgen’s Vectibix

FDA approved the next-generation sequencing-based Extended RAS Panel companion diagnostic from Illumina Inc. (NASDAQ:ILMN) to identify wild-type Ras metastatic colorectal cancer (mCRC) patients who are eligible for treatment with Vectibix panitumumab from Amgen Inc. (NASDAQ:AMGN). The diagnostic runs on Illumina’s MiSeqDx system.

Amgen and Illumina partnered in 2014 to develop and commercialize a Vectibix companion diagnostic (see BioCentury, Jan. 20, 2014)...